Announced Date: 2025-12-04 (December 4, 2025)<\/p>\n\n\n\n
Licensor (Seller): Kelun-Biotech (China)<\/p>\n\n\n\n
Licensee (Buyer): Crescent Biopharma (US) (Nasdaq: CBIO),<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Kelun’s Asset Name: SKB105 (CR-003) <\/p>\n\n\n\n
Asset Modality: Antibody-drug conjugate (ADC) <\/p>\n\n\n\n
Antibody Target: integrin beta-6 (ITGB6)-directed, fully human IgG1 monoclonal antibody<\/p>\n\n\n\n
ADC Payload: topoisomerase 1 inhibitor payload<\/p>\n\n\n\n
ADC Linker: clinically validated cleavable linker<\/p>\n\n\n\n
Potential Indication: treatment of solid tumors<\/p>\n\n\n\n
Current Stage: Clinic-ready<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Authority:<\/p>\n\n\n\n
Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture and commercialize CR-001 in Greater China (including mainland China, Hong Kong, Macau and Taiwan). <\/p>\n\n\n\n
Crescent \u2019s lead program CR-001, a PD-1 x VEGF bispecific antibody<\/p>\n\n\n\n
.<\/p>\n\n\n\n
In addition, Kelun-Biotech has granted Crescent exclusive rights to research, develop, manufacture and commercialize SKB105 in the United States, Europe and all other markets outside of Greater China. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
The partnership includes the development of these candidates as monotherapies, and also the evaluation of CR-001 in combination with SKB105. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
Both Crescent and Kelun-Biotech have the right to independently develop CR-001 in additional combinations, including combinations of CR-001 with proprietary ADC pipeline assets.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Payment Detail:<\/p>\n\n\n\n
Kelun-Biotech will receive an upfront payment of US$80 million from Crescent and is also eligible to receive additional milestones of up to US$1.25 billion, plus tiered middle single-digit to low double-digit royalties on net sales of SKB105. <\/p>\n\n\n\n
Kelun-Biotech is also eligible to receive additional payment from Crescent if Crescent undergoes a near-term change of control or enters into a sublicense agreement with a third party. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
Crescent will receive an upfront payment of US$20 million from Kelun-Biotech and is also eligible to receive additional milestones of up to US$30 million, plus tiered low to middle single digit royalties on net sales of CR-001.<\/p>\n\n\n\n
<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:<\/p>\n\n\n\n
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics – Thu, 12\/04\/2025 – 06:30<\/a><\/p>\n\n\n\n .<\/p>\n\n\n\n